Qiagen cuts FY26 EPS view to ‘at least’ $2.43 from ‘at least’ $2.50

Consensus $2.51. The company states: “QIAGEN (QGEN) has updated its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). Key factors include headwinds from reduced QuantiFERON immigration testing demand, sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least $2.43 CER (previously at least $2.50 CER). QIAGEN expects stronger growth trends in the second half of 2026, supported by the end of headwinds from the discontinuation of NeuMoDx and Dialunox, benefits from recent and planned product launches, sequential improvement in QuantiFERON sales and contributions from the Parse acquisition tracking ahead of the original target for 2026.”